Related content

Role of surgeon volume in radical prostatectomy outcomes - Hu JC, Gold KF, Pashos CL, Mehta SS, Litwin MS, Departments of Urology and Health Services, University of California, Los Angeles, David Geffen School of Medicine and School of Public Health, Los Angeles, CA. J Clin Oncol 2003:21:401-405

By Smith J.A.  

Urologic Oncology: Seminars and Original Investigations, Vol. 21, Iss. 6, 2003-11 ,pp. : 480-480

Elsevier

Access to resources Recommend Favorite

Critical review of complementary therapies for prostate cancer - Wilkinson S, Chodak GW, Midwest Prostate and Urology Health Center, Weiss Memorial Hospital, Chicago, IL. J Clin Oncol 2003;21:2199-2210

By Chatta G.  

Urologic Oncology: Seminars and Original Investigations, Vol. 21, Iss. 6, 2003-11 ,pp. : 491-491

Elsevier

Access to resources Recommend Favorite

Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. Carducci MA, Padley RJ, Breul J, Vogelzang NJ, Zonnenberg BA, Daliani DD, Schulman CC, Nabulsi AA, Humerickhouse RA, Weinberg MA, Schmitt JL, Nelson JB, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD - J Clin Oncol 2003;21:679-689

By Trump D.L.  

Urologic Oncology: Seminars and Original Investigations, Vol. 21, Iss. 5, 2003-09 ,pp. : 410-411

Elsevier

Access to resources Recommend Favorite

Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF), and TNF-related apoptosis-inducing ligand (TRAIL) in prostate cancer - An J, Sun Y-P, Adams J, Fisher M, Belldegrun A, Rettig MB, Veterans Administration Greater Los Angeles Healthcare System, Los Angeles, CA [J An, Y-PS, MF, MBR]; Millennium Pharmaceuticals, Inc., Cambridge, MA [J Adams]; and University of California at Los Angeles School of Medicine, Los Angeles, CA [AB, MBR].

By Chatta G.  

Urologic Oncology: Seminars and Original Investigations, Vol. 21, Iss. 6, 2003-11 ,pp. : 490-491

Elsevier

Access to resources Recommend Favorite

Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. Rini BI, Zimmerman T, Stadler WM, Gajewski TF, Vogelzang NJ, University of California San Francisco, Comprehensive Cancer Center, San Francisco, CA - J Clin Oncol 2002;20:2017-2024

By Trump D.L.  

Urologic Oncology: Seminars and Original Investigations, Vol. 21, Iss. 5, 2003-09 ,pp. : 412-413

Elsevier

Access to resources Recommend Favorite